TLPPF Quote, Financials, Valuation and Earnings

Immutep has a net margin of -- compared to Telix Pharmaceuticals's net margin of --. Telix Pharmaceuticals's return on equity of 13.56% beat Immutep's return on equity of --.

Telix Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep has an analysts' consensus of $9.50 which suggests that it could grow by 486.42%. Given that Immutep has higher upside potential than Telix Pharmaceuticals, analysts believe Immutep is more attractive than Telix Pharmaceuticals.

Telix Pharmaceuticals has a beta of 2.354, which suggesting that the stock is 135.364% more volatile than S&P 500. In comparison Immutep has a beta of 1.936, suggesting its more volatile than the S&P 500 by 93.574%.

Telix Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals pays -- of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend.

Telix Pharmaceuticals quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. Telix Pharmaceuticals's net income of -- is lower than Immutep's net income of --. Notably, Telix Pharmaceuticals's price-to-earnings ratio is 192.89x while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals is 12.31x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.

Kazia Therapeutics has a net margin of -- compared to Telix Pharmaceuticals's net margin of --. Telix Pharmaceuticals's return on equity of 13.56% beat Kazia Therapeutics's return on equity of -1083.16%.

Telix Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics has an analysts' consensus of $2.98 which suggests that it could grow by 351.8%. Given that Kazia Therapeutics has higher upside potential than Telix Pharmaceuticals, analysts believe Kazia Therapeutics is more attractive than Telix Pharmaceuticals.

Telix Pharmaceuticals has a beta of 2.354, which suggesting that the stock is 135.364% more volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 2.285, suggesting its more volatile than the S&P 500 by 128.451%.

Telix Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals pays -- of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend.

Telix Pharmaceuticals quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. Telix Pharmaceuticals's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, Telix Pharmaceuticals's price-to-earnings ratio is 192.89x while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals is 12.31x versus 0.01x for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Opthea has a net margin of -- compared to Telix Pharmaceuticals's net margin of --. Telix Pharmaceuticals's return on equity of 13.56% beat Opthea's return on equity of --.

Telix Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Opthea has an analysts' consensus of $1.33 which suggests that it could fall by -60.9%. Given that Opthea has higher upside potential than Telix Pharmaceuticals, analysts believe Opthea is more attractive than Telix Pharmaceuticals.

Telix Pharmaceuticals has a beta of 2.354, which suggesting that the stock is 135.364% more volatile than S&P 500. In comparison Opthea has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.594%.

Telix Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Telix Pharmaceuticals pays -- of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend.

Telix Pharmaceuticals quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. Telix Pharmaceuticals's net income of -- is lower than Opthea's net income of --. Notably, Telix Pharmaceuticals's price-to-earnings ratio is 192.89x while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Telix Pharmaceuticals is 12.31x versus 2,182.10x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.